$6M Funded Breakthrough: Lobe Sciences Unveils Revolutionary Psilocin Treatment for Chronic Cluster Headaches

Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025

VANCOUVER, B.C. / ACCESS Newswire / September 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its…

$6M Funded Breakthrough: Lobe Sciences Unveils Revolutionary Psilocin Treatment for Chronic Cluster Headaches

Biotech firm Lobe Sciences to present L-130 Conjugated Psilocin™ therapy at Clusterbusters 2025. Company secured $6M funding with $20M option for FDA submission of chronic headache treatment.